Provided by Tiger Trade Technology Pte. Ltd.

Rallybio Corp.

0.7778
+0.05998.34%
Post-market: 0.7775-0.0003-0.04%17:24 EST
Volume:291.08K
Turnover:222.70K
Market Cap:32.86M
PE:-2.46
High:0.7950
Open:0.7399
Low:0.7350
Close:0.7179
52wk High:1.08
52wk Low:0.2201
Shares:42.24M
Float Shares:20.32M
Volume Ratio:1.39
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3160
EPS(LYR):-1.3268
ROE:-21.17%
ROA:-28.35%
PB:0.52
PE(LYR):-0.59

Loading ...

Rallybio Corporation Reports Strong Q3 2025 Results

TIPRANKS
·
Nov 07

UPDATE: Rallybio Q3 Adj. EPS $(0.14) Beats $(0.21) Estimate, Sales $212.000K Beat $66.667K Estimate

Benzinga
·
Nov 06

Rallybio posts Q3 net income of $16 million

Reuters
·
Nov 06

BRIEF-Rallybio Q3 Net Income USD 16.016 Million

Reuters
·
Nov 06

Rallybio Corp - Cash Runway Extended Through 2027

THOMSON REUTERS
·
Nov 06

Rallybio Corp - Net Loss $0.36 per Common Share for Q3

THOMSON REUTERS
·
Nov 06

Rallybio’s RLYB116 Study: A Potential Game-Changer in Hematologic and Autoimmune Disease Treatment

TIPRANKS
·
Oct 28

Rallybio Completes Dosing of First Cohort in Rlyb116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

THOMSON REUTERS
·
Sep 25

Rallybio Corp: Data Readouts for Completed Study Expected in 4Q 2025

THOMSON REUTERS
·
Sep 25

Rallybio Receives $12.5 Million Equity Milestone Payment From Recursion for Advancement of REV102 Program

THOMSON REUTERS
·
Sep 03

Rallybio Corp -

THOMSON REUTERS
·
Sep 03

Rallybio Corporation Announces Initiation of Additional Preclinical Studies for REV102, Secures $12.5 Million Milestone Payment from Recursion

Reuters
·
Sep 03

Rallybio Corporation Faces Nasdaq Delisting Threat; Granted Extension to Regain Compliance with Minimum Bid Price Requirement

Reuters
·
Aug 30

Rallybio Q2 EPS $(0.22) Beats $(0.24) Estimate, Sales $212.000K Down From $299.000K YoY

Benzinga
·
Aug 07

Rallybio Q2 revenue falls, net loss narrows

Reuters
·
Aug 07

Rallybio Corp: Cash Runway Extended Into Mid-2027

THOMSON REUTERS
·
Aug 07

Rallybio Q2 Net Income USD -9.703 Million

THOMSON REUTERS
·
Aug 07

Rallybio Q2 Operating Expenses USD 10.269 Million

THOMSON REUTERS
·
Aug 07

Sector Update: Health Care Stocks Advance in Afternoon Trading

MT Newswires Live
·
Jul 09

Rallybio Corporation Divests Interest in REV102 Program to Recursion Pharmaceuticals for Up to $25 Million

Reuters
·
Jul 08